(HALO) Halozyme Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US40637H1095

Enzyme, Injection, Antibody, Oncology, Autoimmune

Stock: Biotechnology
Age 21.9y

MCap 8,282m
Avg Vol 1.37M (99.7M USD)

Beta 0.541
Volatility 37.22%

EPS (Earnings per Share)

EPS CAGR: -40.72%
EPS Trend: 42.8%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: 39.38%
Rev. Trend: 91.7%

Last SUE: 0.77
Qual. Beats: 0

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	37.2%
Value at Risk 5%th	52.7%
Relative Tail Risk	-13.91%

Reward TTM
Sharpe Ratio	0.72
Alpha	20.30
CAGR/Max DD	0.26

Character TTM
Hurst Exponent	0.301
Beta	0.541
Beta Downside	0.590

Drawdowns 3y
Max DD	43.17%
Mean DD	18.49%
Median DD	19.35%

Description: HALO Halozyme Therapeutics January 08, 2026

Halozyme Therapeutics (NASDAQ:HALO) is a biopharma company that commercializes its patented recombinant human hyaluronidase enzyme (rHuPH20) to enable sub-cutaneous delivery of a wide range of injectable therapeutics, from monoclonal antibodies to small-molecule drugs.

Its flagship products include Hylenex ® (rHuPH20 for enhanced SC absorption), XYOSTED™ (SC testosterone replacement), and a pipeline of enzyme-device combos such as ATRS-1902. Halozyme also supplies the enzyme platform for partnered biologics-including Herceptin Hylecta, Phesgo, Mabthera SC, HYQVIA, Ocrevus, DARZALEX, and several HIV, oncology, and autoimmune indications-through licensing deals with Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, BMS, and others.

Key recent metrics: Q4 2023 revenue of $84 million (+27 % YoY), cash and equivalents of $310 million, and a 2024 guidance of $350-$380 million total revenue, driven largely by expanding SC formulations in oncology and immunology. The global sub-cutaneous drug delivery market is projected to grow at a CAGR of ~9 % through 2030, providing a secular tailwind for Halozyme’s enzyme platform.

Strategically, the company’s value hinges on the breadth of its partnership network and the ability to monetize rHuPH20 through royalty streams and upfront payments; any material loss of a major partner (e.g., Roche) would materially downgrade its cash-flow outlook.

For a deeper, data-driven look at Halozyme’s valuation assumptions and scenario analysis, you may find the research tools on ValueRay useful.

Piotroski VR‑10 (Strict, 0-10) 9.0

Net Income (595.5m TTM) > 0 and > 6% of Revenue (6% = 74.6m TTM)

FCFTA 0.27 (>2.0%) and ΔFCFTA 8.58pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 39.55% (prev 107.5%; Δ -67.93pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.28 (>3.0%) and CFO 611.0m > Net Income 595.5m (YES >=105%, WARN >=100%)

Net Debt (1.09b) to EBITDA (886.4m) ratio: 1.23 <= 3.0 (WARN <= 3.5)

Current Ratio 1.59 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (122.3m) change vs 12m ago -6.00% (target <= -2.0% for YES)

Gross Margin 84.55% (prev 78.34%; Δ 6.21pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 57.28% (prev 44.73%; Δ 12.56pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 43.01 (EBITDA TTM 886.4m / Interest Expense TTM 17.8m) >= 6 (WARN >= 3)

Altman Z'' 4.85

(A) 0.22 = (Total Current Assets 1.33b - Total Current Liabilities 837.2m) / Total Assets 2.22b

(B) 0.23 = Retained Earnings (Balance) 502.1m / Total Assets 2.22b

(D) 0.28 = Book Value of Equity 480.0m / Total Liabilities 1.72b

Total Rating: 4.85 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 89.48

1. Piotroski 9.0pt

2. FCF Yield 6.63%

3. FCF Margin 48.47%

4. Debt/Equity 3.00

5. Debt/Ebitda 1.23

6. ROIC - WACC (= 24.96)%

7. RoE 141.6%

8. Rev. Trend 91.65%

9. EPS Trend 42.84%

What is the price of HALO shares?

As of January 22, 2026, the stock is trading at USD 71.71 with a total of 1,034,214 shares traded.
Over the past week, the price has changed by -1.71%, over one month by +5.21%, over three months by +7.22% and over the past year by +28.19%.

Is HALO a buy, sell or hold?

Halozyme Therapeutics has received a consensus analysts rating of 3.63. Therefor, it is recommend to hold HALO.

Strong Buy: 2
Buy: 2
Hold: 3
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the HALO price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	77.1	7.6%
Analysts Target Price	77.1	7.6%
ValueRay Target Price	76.4	6.6%

HALO Fundamental Data Overview January 22, 2026

P/E Trailing = 14.8587
P/E Forward = 8.4962
P/S = 6.664
P/B = 16.618
P/EG = -2.5
Revenue TTM = 1.24b USD
EBIT TTM = 763.7m USD
EBITDA TTM = 886.4m USD
Long Term Debt = 800.1m USD (from longTermDebt, last quarter)
Short Term Debt = 710.7m USD (from shortTermDebt, last quarter)
Debt = 1.51b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.09b USD (from netDebt column, last quarter)
Enterprise Value = 9.09b USD (8.28b + Debt 1.51b - CCE 702.0m)
Interest Coverage Ratio = 43.01 (Ebit TTM 763.7m / Interest Expense TTM 17.8m)
EV/FCF = 15.09x (Enterprise Value 9.09b / FCF TTM 602.4m)
FCF Yield = 6.63% (FCF TTM 602.4m / Enterprise Value 9.09b)
FCF Margin = 48.47% (FCF TTM 602.4m / Revenue TTM 1.24b)
Net Margin = 47.91% (Net Income TTM 595.5m / Revenue TTM 1.24b)
Gross Margin = 84.55% ((Revenue TTM 1.24b - Cost of Revenue TTM 192.1m) / Revenue TTM)
Gross Margin QoQ = 84.41% (prev 85.77%)
Tobins Q-Ratio = 4.09 (Enterprise Value 9.09b / Total Assets 2.22b)
Interest Expense / Debt = 0.28% (Interest Expense 4.30m / Debt 1.51b)
Taxrate = 19.97% (43.7m / 219.0m)
NOPAT = 611.2m (EBIT 763.7m * (1 - 19.97%))
Current Ratio = 1.59 (Total Current Assets 1.33b / Total Current Liabilities 837.2m)
Debt / Equity = 3.00 (Debt 1.51b / totalStockholderEquity, last quarter 503.9m)
Debt / EBITDA = 1.23 (Net Debt 1.09b / EBITDA 886.4m)
Debt / FCF = 1.81 (Net Debt 1.09b / FCF TTM 602.4m)
Total Stockholder Equity = 420.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 27.45% (Net Income 595.5m / Total Assets 2.22b)
RoE = 141.6% (Net Income TTM 595.5m / Total Stockholder Equity 420.7m)
RoCE = 62.56% (EBIT 763.7m / Capital Employed (Equity 420.7m + L.T.Debt 800.1m))
RoIC = 31.68% (NOPAT 611.2m / Invested Capital 1.93b)
WACC = 6.72% (E(8.28b)/V(9.79b) * Re(7.91%) + D(1.51b)/V(9.79b) * Rd(0.28%) * (1-Tc(0.20)))
Discount Rate = 7.91% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -3.38%
[DCF Debug] Terminal Value 85.53% ; FCFF base≈518.5m ; Y1≈639.6m ; Y5≈1.09b
Fair Price DCF = 201.2 (EV 24.75b - Net Debt 1.09b = Equity 23.66b / Shares 117.6m; r=6.72% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 42.84 | EPS CAGR: -40.72% | SUE: -4.0 | # QB: 0
Revenue Correlation: 91.65 | Revenue CAGR: 39.38% | SUE: 0.77 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.82 | Chg30d=+0.015 | Revisions Net=-2 | Analysts=2
EPS next Year (2026-12-31): EPS=8.21 | Chg30d=+0.080 | Revisions Net=+1 | Growth EPS=+31.3% | Growth Revenue=+25.8%

Additional Sources for HALO Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle